How Gilead is positioning Veklury vs. such COVID antivirals as Paxlovid
Gilead Sciences Inc. GILD, -0.45% has steadily expanded the use of Veklury while much of the nation’s attention has shifted to the arrival of new antivirals that can be picked up at a pharmacy counter.
The authorization sent Gilead’s stock soaring, hitting a three-year high of $80.00 on April 30, the day before the anticipated authorization. Shares have since pulled back, with Gilead’s stock closing at $61.77 on Tuesday. But the authorizations at the end of last year of Pfizer Inc.’s PFE, +1.03% Paxlovid and Merck’s Lagevrio shifted interest toward COVID-19 medications that don’t require a trip to an infusion center.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Masks are off, COVID rates are up and musicians are once again on edge about touringA slew of acts have canceled tour dates as COVID cases rise once again, casting a pall over what was shaping up to be a record-setting concert season.
Read more »
White House warns U.S. will lose first place in global line without more COVID fundingAs drugmakers develop the next generation of therapies, the White House is warning that if Congress doesn't act urgently the U.S. will have to take a number.
Read more »
White House announces expanded access to antiviral pills for COVIDThe U.S. has ordered enough supply of the pills for 20 million people.
Read more »
Americans who haven't had COVID-19 are now in the minority following omicron surge
Read more »
Harris positive for COVID-19, Biden not ‘close contact’BREAKING: The White House reports that Vice President Kamala Harris has tested positive for COVID-19 on both rapid and PCR tests, and said she “has exhibited no symptoms.” Harris is vaccinated and also got a booster dose.
Read more »